

Diabetes & Obesity

RESEARCH REVIEW™

Making Education Easy

Issue 157 – 2022

In this issue:

- Estimating impact of diet choice on life expectancy
- Changes in food and drink purchases following advertising restrictions
- Progression to diabetes among older adults with prediabetes
- Weight loss after adding time-restricted eating to calorie restriction
- Assessment of NZ's insulin pump special eligibility criteria
- Measures to promote healthy food purchases in supermarkets
- Artificial sweeteners increase cancer risk
- Adding alarms to flash glucose monitoring in type 1 diabetes
- Effects of CGM technologies on glycaemic control in type 1 diabetes
- Automated decision support system for insulin dose adjustments

Abbreviations used in this issue

CGM = continuous glucose monitoring
CSII = continuous subcutaneous insulin infusion
HbA_{1c} = glycosylated haemoglobin
HR = hazard ratio
RCT = randomised controlled trial

Welcome to issue 157 of Diabetes and Obesity Research Review.

This month's issue begins with research estimating how much a person's life expectancy could be increased if they were to adopt a healthier diet. This is followed by research investigating the impact that restricting advertisements for foods high in salt, sugar or fat across the public transport network in London had on consumers' purchases of these and healthier products. There is also similar research from the UK investigating the impact of interventions instigated by major UK grocery stores to promote selection of healthier products by their shoppers. Local research is represented by a survey of NZ CSII prescribers on whether they think the special authority criteria required by PHARMAC for CSII use in this country are fit for purpose.

Thank you for the comments and feedback you have sent us – we look forward to receiving more.

Best regards,

Professor Jeremy Krebs

jeremykrebs@researchreview.co.nz

Estimating impact of food choices on life expectancy

Authors: Fadnes LT et al.

Summary: Life expectancy changes according to diet were estimated in this modelling study from the US that used data from the 2019 Global Burden of Disease study. It was estimated that a sustained change from a typical Western diet to an optimal diet of increased intake of whole grains, legumes, fish, fruits, vegetables and nuts and decreased red and processed meat, sugar-sweetened beverage and refined grain intake from age 20 years would increase life expectancy by 10.7 years for women and 13.0 years for men. The largest gains were seen for increased legume, whole grain and nut consumption and reductions in red and processed meat consumption. Switching to an optimised diet at age 60 years was estimated to increase life expectancy for women and men by 8.0 and 8.8 years, respectively, and the estimated increase of switching at age 80 years was 3.4 years (both sexes). Switching from a typical diet to a feasible-approach diet (midway between a typical Western and an optimal diet) at age 20 years was estimated to increase life expectancy by 6.2 years for women and by 7.3 years for men.

Comment: As these authors point out, interpreting, integrating and really using the incredible wealth of data from nutritional research is extremely difficult. Nutrition research is very complex with many inter-related variables, outcomes of interest, populations studied and study designs making comparison of studies difficult and synthesising outcomes almost impossible. This study takes an interesting approach by using data from the 2019 Global Burden of Disease study and modelling life expectancy for men and women across age brackets if they were to adopt and sustain a dietary pattern, for which general agreement represents an optimised diet. This is a pattern rich in wholegrains, legumes, fish and fruit and vegetables with minimal refined carbohydrate, red meat and processed meat. A common criticism of promoting such a diet is the sustainability or adherence over the long term, in part because the changes required for many are quite extreme, so the authors have also modelled a 'feasible diet' with intakes between ideal and typical Western diets. The findings are dramatic with major increases in life expectancy across the board, which not surprisingly are greater if adopted at a younger age.

Reference: *PLoS Med* 2022;19:e1003889

[Abstract](#)

CURB APPETITE¹

TAKE BACK CONTROL. DUROMINE SHOWED A MEAN WEIGHT LOSS OF 9.1KG AT 12 WEEKS.*²

*Patients taking Duromine continuously (n=17) had a mean weight loss of 9.1kg at 12 weeks vs 4.5kg in the placebo group (n=22) (p-value not stated)

DUROMINE™
PHENTERMINE

PUSHON.CO.NZ

References: 1. Duromine Data sheet, January 2018. 2. Munro JF, Maccaish A, C, Wilson EM, Duncan UP. Comparison of Continuous and Intermittent Anorectic Therapy in Obesity. *Brit Med J* 1968;1:352-354.

DUROMINE™ IS A C5 CONTROLLED DRUG. **DUROMINE™** IS AN UNFUNDED MEDICINE - A PRESCRIPTION CHARGE WILL APPLY. PLEASE REVIEW FULL DATA SHEET BEFORE PRESCRIBING AVAILABLE AT WWW.MEDSAFE.GOV.NZ OR PHONE Freephone 0508 375394. Minimum Data Sheet Information (phentermine). **DUROMINE™ Indications:** For the management of obesity as a short-term adjunct in a medically monitored weight loss programme based on exercise, diet and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m² or greater. **DUROMINE™** may appropriately be initiated in overweight patients with a lower BMI when risk of morbidity from other medical conditions is increased. **Dosage and Administration:** The usual starting dose in adults and children over 12 years is 30 mg once daily at breakfast. Continuous or intermittent maintenance dose is 15 mg to 30 mg once daily depending on responsiveness. Patients require medical review after a defined course of treatment, which should not exceed three months. Available in 15 mg and 30 mg capsules. **Contraindications:** Pulmonary artery hypertension, heart valve abnormalities, heart murmurs, moderate to severe hypertension, cerebrovascular disease, severe cardiac disease including arrhythmias, advanced arteriosclerosis, hypersensitivity to sympathomimetic drugs, hyperthyroidism, psychiatric illnesses, glaucoma, drug/alcohol abuse or dependence, concomitant MAOIs or within 14 days of MAOI use. **Precautions:** Short term monotherapy only. Co-administration of drug products for weight loss is not recommended. There have been no reported cases of valvular heart disease occurring with phentermine alone. Use with caution in mild hypertension, established coronary artery disease, epilepsy, and in those receiving insulin, oral hypoglycaemic agents or psychotropic agents. **Adverse Effects:** The most common are palpitations, tachycardia, elevation of blood pressure and precordial pain. Others included restlessness, insomnia, nausea, and dry mouth. Psychotic episodes, hallucinations and serious cardiovascular or cerebrovascular events are rare. Full Data Sheet and Consumer Medicine Information is available from Medsafe at www.medsafe.govt.nz. iNova Pharmaceuticals (Australia) Pty Limited, Level 10, 12 Help Street, Chatswood NSW 2067, Australia. Distributed in New Zealand by Radiant Health Ltd, c/o Supply Chain Solutions, 74 Westney Road, Airport Oaks, Auckland. For all product enquiries: New Zealand Toll Free: 0508 375 394. TAPS NA 12719. NZ2021-02-0010. February 2021.

 Radiant Health

For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

a RESEARCH REVIEW™ publication



Jardiance®
(empagliflozin)

FULLY FUNDED
with Special Authority criteria*
for the treatment of T2D

For your patients with type 2 diabetes[†]

THE POWER TO ACCOMPLISH MORE
Above and beyond glycaemic control^{†,2}

Not an actual patient.

[†]38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).² *JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. Jardiance is fully funded for the treatment of T2DM. Jardiance is not funded for the treatment of heart failure with reduced ejection fraction. [†]In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. ²The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE[®] (p<0.001).^{1,2} JARDIANCE[®] Data Sheet 2021 Zinman B et al. N Engl J Med. 2015;373(22):2117-2128

JARDIANCE[®] empagliflozin 10mg, 25mg film coated tablets. Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp> **INDICATION:** Type 2 diabetes mellitus - Glycaemic control: Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: Monotherapy - When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; Add-on combination therapy - With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. **Prevention of cardiovascular (CV) events:** In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, Jardiance should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **Heart failure:** In adult patients with heart failure (NYHA class II-IV) and reduced ejection fraction, with or without type 2 diabetes mellitus: to reduce the risk of hospitalisation for heart failure; to slow kidney function decline. **DOSAGE AND ADMINISTRATION:** Type 2 diabetes mellitus: Recommended starting dose is 10mg once daily. Patients with type 2 diabetes mellitus tolerating 10mg once daily and requiring additional glycaemic control, increase dose to 25mg once daily. **Heart failure:** Recommended dose is 10mg once daily. Can be taken with or without food. No dose adjustment is recommended based on age, patients with eGFR ≥30mL/min/1.73m² (T2DM) or ≥20mL/min/1.73m² (HF), or hepatic impairment. When Jardiance is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with severe renal impairment (T2DM: eGFR <30mL/min/1.73m²). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); contraindicated when eGFR <30mL/min/1.73m² (T2DM); not recommended when eGFR <20mL/min/1.73m² (HF); assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); complicated urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics; insulin and SU interference with 15-anhydroglucitol assay. **ADVERSE REACTIONS:** Very common: hypoglycaemia (when used with metformin in combination with SU or insulin - patients with T2DM); volume depletion (patients with HF). Common: hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin - patients with T2DM); hypoglycaemia (patients with HF); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus (patients with T2DM); allergic skin reactions (e.g. rash, urticaria); increased urination (patients with T2DM); thirst (patients with T2DM); serum lipids increased; volume depletion (patients aged ≥75 years); constipation. For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption. Through inhibition of SGLT2, excessive glucose is excreted in the urine. Empagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, increasing tubuloglomerular feedback and reducing intraglomerular pressure, lowering both pre- and afterload of the heart, and downregulating sympathetic activity. **PRESCRIPTION MEDICINE - JARDIANCE** is a funded medicine - Restrictions apply: Pharmaceutical Schedule, Special Authority. Jardiance is fully funded for the treatment of T2DM. Jardiance is not funded for the treatment of heart failure with reduced ejection fraction. JARDIANCE[®] is a registered trademark of Boehringer Ingelheim. BOEHRINGER INGELHEIM (N.Z.) Ltd. Level 3, 2 Osterley Way, Manukau, Auckland 2004. TAPS MR9151/PC-NZ-100168 April 2022 BOE000408

 **Boehringer Ingelheim**
Boehringer Ingelheim (NZ) Ltd.
PO Box 76216 Manukau City,
Auckland 2241. Phone 0800 802 461


Eli Lilly and Company (NZ) Ltd.
PO Box 109197 Newmarket,
Auckland 1149. Phone 0800 500 056
NZBN 9429039560643

Changes in household food and drink purchases following restrictions on the advertisement of high fat, salt, and sugar products across the Transport for London network

Authors: Yau A et al.

Summary: This controlled interrupted time-series analysis of >5 million take-home food and drink purchases recorded by 977 randomly selected households in London (intervention) and 933 from the North of England (control) estimated average weekly household purchases of energy and nutrients from products high in fat, salt and sugar during the postintervention period (44 weeks) versus a counterfactual derived from the control group and pre-intervention (36 weeks) period; the intervention was restriction on advertising products high in fat, salt and sugar implemented in Feb 2019. Compared with the counterfactual, intervention households purchased 6.7% less energy from products high in fat, salt and sugar, including a 19.4% reduction in energy from chocolate and confectionery purchases.

Comment: There have been calls for restrictions to advertising of unhealthy foods as a high-level intervention to reduce rates of obesity for well over a decade now. It has been hard to get action on this at a political level, in part because of strong food industry lobbying, which often relates to difficulties in defining healthy and unhealthy foods, and in part because of limited evidence for efficacy of such an approach. This study provides some support for restriction on advertising of products with high fat, salt and sugar. In a population case-control study in the UK, average weekly household purchasing of high fat, salt and sugar products was compared between an area with restricted outdoor advertising and a control population. Although there are a number of limitations to the design as acknowledged by the authors, there was compelling evidence of a beneficial effect of the restriction on advertising. Let's face it, why would the food industry waste money on advertising if it didn't increase sales!

Reference: *PLoS Med* 2022;19:e1003915
[Abstract](#)

[CLICK HERE](#)

to read previous issues of
Diabetes & Obesity Research Review



NZMA
New Zealand Medical Association
Rotorua GP CME
General Practice Conference & Medical Exhibition

09-12 JUNE 2022
ENERGY EVENTS CENTRE
ROTORUA

   gpcme.co.nz

For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

a RESEARCH REVIEW™ publication




NEW

trulicity®
dulaglutide once-weekly injection

**New Zealand's only
funded GLP-1 RA for
adults with type 2
diabetes.*¹⁻³**

**Special Authority Criteria Apply.²*

Progression to diabetes among older adults with hemoglobin A_{1c}-defined prediabetes in the US

Authors: Koyama AK et al.

Summary: This research estimated annual progression rates of prediabetes (defined as HbA_{1c} level 5.7–6.4%) to diabetes using electronic health record data for 50,152 outpatients aged ≥65 years from the longitudinal US LEADR study. Over a median 2.3 years of follow-up, the crude incidence of diabetes was 53 per 1000 person-years, for an annual progression rate of 5.3%. Patient groups defined by age, sex, race/ethnicity, family history of diabetes, hypertension diagnosis, social vulnerability index, BMI and HbA_{1c} level all had annual progression to diabetes rates of ≥5.0% except for groups represented by the lowest social vulnerability index, BMI <30 kg/m² or a baseline HbA_{1c} level of 5.7–5.9%. The annual progression of diabetes rate among participants with a BMI of 18.5–24.9 kg/m² was 3.5%, compared with 7.6% for those with a BMI of ≥40 kg/m², and for participants with HbA_{1c} levels of 5.7–5.9% it was 2.8%, compared with 8.2% for those with an HbA_{1c} level in the 6.0–6.4% range.

Comment: The relevance and importance of prediabetes continues to be debated. Since moving to HbA_{1c} level as the screening tool for diagnosis of diabetes, and therefore prediabetes, there has been great uncertainty about the real risk of prediabetes as we define it in NZ. Older data, based on oral glucose tolerance tests, have suggested a significant lifetime risk of progression to diabetes and cardiovascular disease, but contemporary data from those defined by HbA_{1c} level are largely lacking. What we do have from NZ primary care data suggests that the risk of progression is not as high as previously thought. This current study adds to this discussion, albeit that the data are from the US, where prediabetes is defined at a lower HbA_{1c} level threshold, and of course the population is not representative of NZ. Nevertheless, these are useful additional data for the ongoing discussion of who we should be targeting for intervention.

Reference: *JAMA Netw Open* 2022;5:e228158
[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).



South GP CME
General Practice Conference & Medical Exhibition

11-14 AUGUST 2022
TE PAE CONFERENCE CENTRE
CHRISTCHURCH

[gpcme.co.nz](#)

**PLEASE REVIEW FULL DATA SHEET BEFORE PRESCRIBING. FULL DATA SHEET CAN BE
ACCESSED AT WWW.MEDSAFE.GOV.NZ OR ON REQUEST BY CALLING 0800 500 056.**

TRULICITY® (dulaglutide 1.5mg/0.5mL solution for injection, pre-filled pen [autoinjector]).

PRESCRIPTION MEDICINE. TRULICITY is funded under the New Zealand Pharmaceutical Schedule. Special Authority Criteria apply.

INDICATIONS – TRULICITY is indicated for adult patients with Type 2 diabetes as 1) an adjunct to diet and exercise to improve glycaemic control; and 2) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in those with either established cardiovascular disease or multiple risk factors for cardiovascular disease. **CONTRAINDICATIONS** – Hypersensitivity to dulaglutide or any of the excipients. **PRECAUTIONS** – should not be used in patients with Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; severe gastrointestinal disease – not recommended; acute pancreatitis – discontinue treatment if suspected; hypoglycaemia – combining treatment with sulfonylurea or insulin may increase risk; congestive heart failure – limited therapeutic experience; Use in Pregnancy Category B3. **ADVERSE EFFECTS Clinical Trials Experience** – Very Common (≥10%) gastrointestinal disorders (nausea, vomiting and diarrhoea), hypoglycaemia (in combination with insulin non-/secretagogues and/or insulin); Common (≥1 and <10%) abdominal pain, decreased appetite, dyspepsia, fatigue, hypoglycaemia (as monotherapy), immunogenicity, atrial fibrillation. **DOSAGE AND ADMINISTRATION** – **Dosage:** Adults (≥18 years): 1.5 mg once weekly, at any time of day, independently of meals. Elderly Patients (≥65 years): dose adjustment not required. Children and adolescents (<18 years): safety and effectiveness have not been established. Renal Impairment: no dose adjustment is required in mild, moderate or severe renal impairment; not recommended in end-stage renal disease. Hepatic Impairment: no dose adjustment required. **Administration:** subcutaneous injection in the abdomen, thigh or upper arm. Should not be administered intravenously or intramuscularly. Single-use in one patient only. Discard the pen once the injection is completed. Please review full Data Sheet before prescribing. Full Data Sheet is available on request from Eli Lilly. Eli Lilly and Company (NZ) Limited, PO Box 109 197, Newmarket, Auckland 1149. Phone 0800 500 056. Based on Data Sheet approved 12 August 2021.

Abbreviation: GLP-1 RA, Glucagon-like peptide-1 receptor agonist.

References: **1.** Trulicity Data Sheet August 2021. **2.** Pharmaceutical Schedule. Available at: <https://schedule.pharmac.govt.nz/ScheduleOnline.php>. Last Accessed April 2022. **3.** Trulicity Product Detail. Medsafe. Available at: <https://www.medsafe.govt.nz/regulatory/ProductDetail.asp?ID=21737>. Last accessed April 2022.

Trulicity® is a registered trademark of Eli Lilly and Company.
Eli Lilly and Company (NZ) Limited. PO Box 109 197 Newmarket, Auckland 1149,
New Zealand. NZBN 9429039560643. Telephone 0800 500 056.
PP-DG-NZ-0075. TAPS BG2103. ELI4570
Date of preparation: April 2022.



Calorie restriction with or without time-restricted eating in weight loss

Authors: Liu D et al.

Summary: Obese individuals were randomised to calorie restriction (1500–1800 kcal/day for men; 1200–1500 kcal/day for women) with or without time-restricted eating (i.e. eating only between 8:00AM and 4:00PM) for 12 months; 118 of the 139 randomised participants completed their 12-month follow-up visit. Mean weight losses from baseline at 12 months (primary outcome) in the time restriction and control (calorie restriction-only) groups were 8.0 and 6.3kg, respectively ($p=0.11$), with similar outcomes seen for change in waist circumference, BMI, bodyfat, body lean mass, blood pressure and metabolic risk factors, and no substantial between-group differences for adverse events.

Comment: The concept of intermittent fasting has become popular in recent years as a strategy to facilitate weight loss and/or improve metabolism. Intermittent fasting may be achieved by either restricting eating to within a set number of hours during the day, or by selecting one or more days of the week to restrict energy intake (commonly the 5:2 diet). This RCT explored whether a time-restricted eating pattern in addition to overall calorie restriction promotes greater weight loss than calorie restriction alone after 12 months. Although the time-restricted group had a mean of 1.8kg greater weight loss, this was not statistically significant, and there was quite a large range of responses in both groups. As is so often the case in RCTs of weight loss, some of the really interesting data can be lost in the group mean changes. What I take from this study is that we do not have evidence to say that time-restricted eating is the best approach to achieve calorie restriction for everyone, but we can say that it is a very good approach for some people. What we would like to know is how to pick those people for whom this would be the best approach!

Reference: *N Engl J Med* 2022;386:1495–504

[Abstract](#)

Insulin pump special eligibility criteria in New Zealand

Authors: Groves M et al.

Summary: These researchers from NZ surveyed prescribers of CSII regarding PHARMAC's current special authority criteria. A substantial majority (88%) of the 94 respondents felt that the special authority criteria for CSII needed updating; however, 75% maintained that CSII funding by PHARMAC should remain under updated special authority criteria. Sixty percent of the respondents indicated that they thought the current criteria did not promote health equity for Māori and Pasifika. Only a third of the respondents reported strict adherence to the criteria. Thematic analyses of free text revealed that the respondents did not believe that the current special authority criteria for CSII reflected quality of life benefits, changes in life course, clinician or patient autonomy or beneficence of CSII.

Comment: We are all familiar with the model of funding for pharmaceuticals in NZ, with the availability and funding being controlled by PHARMAC. This was extended to some medical devices, which included insulin pumps and glucose monitoring devices. We have now had access to funded insulin pumps and associated consumables for people with type 2 diabetes for over a decade, and this paper reports on the views of the health professionals responsible for prescribing these tools. The overwhelming conclusion from this survey is that the current special authority criteria for pumps are no longer fit for purpose. Interestingly, 75% agreed that special authority provisions should remain, but since only 33% strictly adhered to the current ones, it is very clear that they need to be revised to meet the needs of patients and represent the current state of evidence. This must include an incorporation of funding for CGM to enable the optimal use of pump technology, or else we will only see increasing inequity.

Reference: *N Z Med J* 2022;135(1552):82–8

[Abstract](#)

Testing availability, positioning, promotions, and signage of healthier food options and purchasing behaviour within major UK supermarkets

Authors: Piernas C et al.

Summary: This evaluation of six nonrandomised controlled retailer-led intervention studies and one pre/post within-store intervention found that compared with controls: i) stocking low-fat chips next to regular chips led to decreased sales of the latter; ii) increased availability of lower energy biscuits increased sales with reduced sales of regular biscuits, with the difference reaching significance in interrupted time-series models; iii) there was no evidence that placing higher fibre breakfast cereals at eye level increased sales or reduced sales of regular cereal; iv) price promotions on seasonal fruits and vegetables significantly increased sales in interrupted time-series models; v) use of Disney characters to promote nonsugar baked beans and selected fruits increased sales; and vi) there was no evidence of benefit for having labels highlighting lower sugar beverages at shelf level.

Comment: Could supermarkets become part of the solution rather than the problem? There has been a lot of attention on the duopoly we have in NZ with our supermarket chains controlling the food chain. Whilst there has been little political appetite to change this, could we use this situation to the advantage of the country if they are prepared to work together to influence the diets of the population towards a more healthy pattern? This study reports on some of the evidence for supermarket-based interventions. It is muddy to say the least! The absence of randomised trials hinders the interpretation of the data. However, what it does do is raise the possibility for change. What is needed is more community pressure to do so. Supermarkets already collect enormous amounts of data about our purchasing patterns and behaviours. They do this to increase profits. Imagine if they used their data to improve health and wellbeing. We might be a bit more forgiving of the ridiculous profits they make. What am I saying!

Reference: *PLoS Med* 2022;19:e1003952

[Abstract](#)

Artificial sweeteners and cancer risk

Authors: Debras C et al.

Summary: This population-based cohort study from France analysed 708,905 person-years of follow-up diet records from 102,865 adults (78.5% female) to assess cancer risk associated with artificial sweetener intake; aspartame was the most commonly consumed artificial sweetener (60% of intake), followed by acesulfame-K (29%) and sucralose (10%), which were consumed by 28%, 34% and 14% of participants, respectively. Soft drinks, table-top sweeteners and yoghurts were the most common source of artificial sweetener intake. A total of 3358 incident cancer cases were reported, predominantly obesity-related cancers (60%) with high rates of breast and prostate cancers. There was a 13% increased risk of cancer in high- versus non-artificial sweetener consumers (adjusted HR 1.13 [95% CI 1.03, 1.25]). When sweeteners were considered individually, both aspartame and acesulfame-K were associated with significantly increased risks of any cancer (respective HRs 1.15 and HR 1.13); aspartame also increased the risks of breast cancer and obesity-related cancer (1.22 and 1.13). These associations retained significance on sensitivity analyses.

Comment: The issue of whether artificial sweeteners have harmful health effects, and specifically risk for cancer, has been debated for as long as they have been used as sugar substitutes. The argument for using these agents is the reduction in calories from sugar and the direct metabolic effects of high sugar consumption. This epidemiological study has shown an approximately 15% increased risk of cancer generally, and breast and obesity-related cancers specifically, in higher consumers of artificial sweeteners. This is after adjusting for many variables known to increase cancer risk, including obesity. This is not insignificant and raises the question again whether we should be promoting the substitution of these agents for sugar. It certainly suggests that we should promote water over any sweetened beverage.

Reference: *PLoS Med* 2022;19:e1003950

[Abstract](#)

Kindly Supported by



diabetes
new zealand



NEW ZEALAND
RURAL
GENERAL PRACTICE NETWORK



Effectiveness of adding alarms to flash glucose monitoring in adults with type 1 diabetes under routine care

Authors: Boscarì F et al.

Summary: This research assessed switching from 4 weeks using a standard flash glucose monitoring system to 8 weeks using a system with alarms for hypo- and hyperglycaemia in 38 adults with type 1 diabetes who had >4% of time in hypoglycaemia or >40% of time in hyperglycaemia recorded. During the first 4 weeks of use with the alarm-equipped system, time in target glucose level range increased significantly from 52.8% to 57.0%, and time below range fell significantly from 6.2% to 3.4%, as did time with a level <54 mg/dL (from 1.4% to 0.3%) and the coefficient of variation (from 39.6% to 36.1%); similar changes were confirmed 8 weeks after switching systems. There were also improvements recorded for treatment satisfaction and fear of hypoglycaemia. The greatest benefits in glucose level control and treatment satisfaction were noted in participants who had >4% of time in hypoglycaemia at baseline.

Comment: This is a really nice real-world study of great relevance to practice in NZ. Flash glucose monitoring systems have become popular amongst our patients with type 1 diabetes, and until PHARMAC get around to funding them, they remain the most cost-effective subcutaneous glucose monitoring system. The Libre device we currently have is limited by the lack of 'bluetoothing' to a phone or watch, and therefore the ability to set alarms for glucose levels. This can be overcome with additional devices, but really we need the later-generation models. What this study shows is that by using alarms, people can achieve better time in range, and also reduce their fear of hypoglycaemia and improve their general treatment satisfaction. It's a no brainer really.

Reference: *Acta Diabetol*; Published online April 13, 2022

[Abstract](#)

Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus

Authors: Elbalsby M et al.

Summary: This was a systematic review with meta-analysis of data from 15 RCTs investigating adjunctive CGM, five investigating nonadjunctive CGM and two investigating intermittently-scanned CGM, all versus traditional capillary glucose monitoring, in patients with type 1 diabetes. A statistically significant absolute improvement in HbA_{1c} level was seen when data from all three CGM categories were pooled and compared with the comparator (mean difference, -0.22 percentage points [95% CI -0.31, -0.14]), with the strongest effect seen for adjunctive CGM (-0.26% [-0.36, -0.16]). There was also a significant increase in time in target glucose level range of 5.4% for CGM interventions versus the comparator, with the strongest effect seen with nonadjunctive CGM (6.0%).

Comment: This one is for PHARMAC too – the rest of us don't need convincing. The evidence is mounting for the benefits of subcutaneous glucose monitoring in people with type 1 diabetes. This is a systematic review and meta-analysis of RCTs of various forms of CGM versus finger prick capillary glucose level monitoring on glycaemic control. The data are clear that CGM improves glycaemic control as measured by HbA_{1c} level or time in range. What this hides are the other major benefits of CGM, which include satisfaction and quality of life, and reduction in hypoglycaemia. Furthermore, isn't it barbaric that we have a technology available which minimises the need for needles and painful finger pricks in children, avoids the need to wake children overnight and gives parents some sanity, yet we don't fund it.

Reference: *Diabet Med* 2022;e14854

[Abstract](#)

Comparison of insulin dose adjustments made by artificial intelligence based decision support system and by physicians in people with type 1 diabetes using multiple daily injections therapy

Authors: Nimri R et al.

Summary: Twenty physicians from academic centres were surveyed on 17 cases of individuals with type 1 diabetes treated with multiple daily insulin injections with questions on recommended insulin dose adjustments based on glucose level and insulin data; their recommended insulin dose adjustments were compared with an automated decision support system. The automated decision support system was noninferior to the surveyed physicians with respect to agreement and disagreement in the direction of insulin dose adjustment for basal rate, carbohydrate-to insulin ratio and correction factor, although the automated decision support system consistently returned an insulin dose change that was smaller in magnitude to the changes proposed by the physicians.

Comment: We are at risk of becoming redundant and irrelevant! This is an interesting study comparing recommendations for insulin regimen adjustment by expert clinicians across a range of countries with the advice generated by an automated artificial intelligence system. Both were given a set of 17 different sets of data. There was no significant difference in dose adjustments between physicians and the computer, although the computer tended to give more conservative adjustments. We are seeing artificial intelligence at work in the latest pump algorithms for insulin dose adjustments. In that setting, there is a wealth of data input from CGM. However, whether artificial intelligence can be equally effective and safe with fewer and more random datapoints that are typical of people with finger prick capillary monitoring remains unclear. It's all about pattern recognition at the end of the day, but as we know, there are many unpredictable variables that come to play in real people living real lives with type 1 diabetes.

Reference: *Diabetes Technol Ther*, Published online March 24, 2022

[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

Privacy Policy: Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.

Independent commentary by Professor Jeremy Krebs MBChB, FRACP, MD

Professor Krebs is an Endocrinologist with a particular interest in obesity and diabetes. He trained in Endocrinology at Wellington Hospital in New Zealand and then did his doctorate with the Medical Research Council - Human Nutrition Research unit in Cambridge England. His thesis was on the impact of dietary factors on obesity and insulin resistance. Professor Krebs returned to New Zealand in 2002 to take up a consultant Endocrinology post at Wellington Hospital, where he was Clinical Leader of Endocrinology and Diabetes.



FOR FULL BIO [CLICK HERE](#).

RACP MyCPD Program participants can claim **one credit per hour** (maximum of 60 credits per year in Category One – Educational Activities) for reading and evaluating Research Reviews.

Please [CLICK HERE](#) to download CPD Information